Actimmune (interferon gamma-1b) prior authorization for specific diagnoses
Customize your policy alerts
Sign up for all careoregon policy alerts
Know when careoregon releases new policies or updates existing guidance.
Monitor payer policy activity
This guideline governs prior authorization requirements for the medication Actimmune (interferon gamma-1b) for members requiring therapy for certain specified diagnoses (e.g., Chronic Granulomatous Disease, Malignant osteopetrosis) under CareOregon.
No material clinical or coverage changes in this revision.
Coverage Criteria for Actimmune (interferon gamma-1b)
Initial Authorization Criteria
Covered when the following diagnosis is present and prior authorization is obtained:
Approval length noted as 12/31/2039
Approval length noted as 12/31/2039
The source document does not list any explicit exclusions for Actimmune; no separate exclusion criteria are provided in the guideline text.
The guideline does not describe any specific conditions or situations that are considered not medically necessary for Actimmune; no 'not medically necessary' statements appear in the provided text.
Provider Actions, Authorization & Documentation
Actimmune requires prior authorization for specified diagnoses
Actimmune (interferon gamma-1b) use for the listed diagnoses requires prior authorization from CareOregon; the policy lists Chronic Granulomatous Disease and Malignant osteopetrosis as covered diagnoses with authorization. Approval length is documented through 12/31/2039.
No step therapy specified
No step therapy requirements are specified in the guideline for Actimmune; the document does not list any required trials or prior medications before authorization.
Document diagnosis and intended approval length
Provide documentation that supports the diagnosis being treated (e.g., Chronic Granulomatous Disease or Malignant osteopetrosis) and the requested approval length; the guideline identifies the diagnosis and notes approval length through 12/31/2039 as part of the authorization criteria.
- Clinical documentation confirming diagnosis (Chronic Granulomatous Disease or Malignant osteopetrosis)
- Requested approval length consistent with policy (approval length noted as 12/31/2039)
Lack of prior authorization may result in denial
Requests for Actimmune that do not have prior authorization as required by this guideline may be denied; prior authorization is a stated guideline type for the listed diagnoses.
- Ensure prior authorization is obtained before initiating therapy to avoid denial risk
Background
Actimmune (interferon gamma-1b) is addressed in this prior authorization guideline for treatment of certain rare disorders. The document specifies coverage when there is a diagnosis of Chronic Granulomatous Disease or Malignant osteopetrosis, with an approval length through 12/31/2039 noted for the Chronic Granulomatous Disease indication.
Key Diagnoses / Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.